8-K Summary
Registrant: Ikena Oncology, Inc. The request metadata identifies Imagenebio, Inc., but the filing names Ikena Oncology, Inc. as the registrant.
Business Context and Reporting Period
This Form 8-K, dated June 9, 2023, reports the results of Ikena Oncology’s Annual Meeting of Stockholders held on June 9, 2023. The record date was April 18, 2023, when 30,049,528 shares of voting common stock were outstanding.
Key Financial Metrics and Capital Position
The filing is limited to shareholder voting matters and does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes Versus Prior Period
- Stockholders elected David Bonita, M.D., Jean-François Formela, M.D., and Richard Wooster, Ph.D. as Class II directors for terms expiring at the 2026 annual meeting, subject to earlier departure.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, management forecast, new risk disclosures, contingencies, or unusual accounting items. No other matters were submitted to or voted on at the meeting.
Voting Results
| Director nominee | For | Withheld | Broker non-votes |
|---|---|---|---|
| David Bonita, M.D. | 16,468,374 | 7,623,868 | 2,303,836 |
| Jean-François Formela, M.D. | 20,781,723 | 3,310,519 | 2,303,836 |
| Richard Wooster, Ph.D. | 20,784,244 | 3,307,998 | 2,303,836 |
| Auditor ratification | Votes |
|---|---|
| For | 26,385,702 |
| Against | 9,069 |
| Abstain | 1,307 |
| Broker non-votes | 0 |
Facts Investors Should Verify
- Confirm the correct issuer identity: the filing is for Ikena Oncology, Inc., ticker IKNA, rather than Imagenebio, Inc.
- Review the company’s proxy statement filed April 28, 2023 for additional information on the director nominees and proposals.
- Monitor subsequent filings for any changes to the board, auditor relationship, or corporate status.